Skip to main content
Daan Gene Co., Ltd. logo

Daan Gene Co., Ltd. — Investor Relations & Filings

Ticker · 002030 ISIN · CNE000001KP1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,189 across all filing types
Latest filing 2025-03-28 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002030

About Daan Gene Co., Ltd.

https://www.daangene.com

Daan Gene Co., Ltd. specializes in the development and manufacturing of molecular diagnostic products and services. The company focuses on in vitro diagnostic technologies, particularly polymerase chain reaction (PCR) platforms. Its product portfolio includes diagnostic kits for infectious diseases, genetic screening, and oncology, alongside automated nucleic acid extraction systems and real-time PCR instruments. Daan Gene provides comprehensive solutions for clinical laboratories and public health institutions, integrating research, production, and clinical testing services. The organization emphasizes technological innovation in molecular biology to support precision medicine and disease control.

Recent filings

Filing Released Lang Actions
内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2024年度内部控制评价报告' which translates to '2024 Annual Internal Control Evaluation Report' for Guangzhou Da An Gene Co., Ltd. It contains detailed evaluation of the company's internal control effectiveness as of December 31, 2024, including financial and non-financial internal control assessments, control activities, risk assessments, and governance structure. The document is comprehensive and contains substantive content related to internal control evaluation rather than just an announcement or summary. It is not a full annual report (10-K) but a specialized report focusing on internal control evaluation, which aligns with the definition of an Audit Report / Information (AR) as it includes applied accounting principles and internal control results. The length (6990 characters) and detailed content confirm it is a full report, not a brief announcement or certification. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2024
2025-03-28 Chinese
关于2024年度计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Guangzhou Da An Gene Co., Ltd. regarding the asset impairment provision for the fiscal year 2024. It details the amount of impairment, the accounting standards applied, the impact on net profit and equity, and the audit committee's approval. The document is titled as an "announcement" and contains no full financial statements or comprehensive financial report data. It is a regulatory disclosure about accounting estimates and provisions rather than a full annual or interim report. The length is about 4982 characters, which is borderline but the content is clearly an announcement of impairment provisions, not a full report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories like Annual Report (10-K) or Interim Report (IR).
2025-03-28 Chinese
独立董事年度述职报告
Board/Management Information Classification · 95% confidence The document is a detailed annual report by the independent directors of Guangzhou Da An Gene Co., Ltd. for the year 2024. It includes descriptions of their duties, attendance at board and shareholder meetings, committee work, communication with auditors, investigations, and oversight activities. It references compliance with company law and governance codes, and discusses oversight of financial reports and internal controls. The document is a formal report on the independent directors' performance and activities during the fiscal year, not an announcement or a brief summary. It does not contain financial statements but is a management-related report focusing on governance and oversight by independent directors. This fits best under Board/Management Information (MANG), which covers announcements of changes or reports related to the company's board or senior management activities. The length and detail confirm it is not a short announcement or a certification, and it is not a full annual report or audit report. Therefore, the classification is MANG with high confidence.
2025-03-28 Chinese
独立董事2024年度述职报告（朱征夫）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2024 Annual Work Report" for Guangzhou Da An Gene Co., Ltd. It is a detailed report by an independent director about their duties, attendance, committee work, supervision, and evaluation during the 2024 fiscal year. The content focuses on governance, board activities, audit committee involvement, and protection of shareholder interests, especially minority shareholders. It does not contain financial statements or financial performance data but rather a narrative on the director's role and activities. This type of document fits best under Board/Management Information (MANG) as it relates to board member duties and governance reporting rather than a full annual report or audit report. The document length is about 4656 characters, which is sufficient for a detailed report but not a full financial report. Therefore, the classification is MANG with high confidence.
2025-03-28 Chinese
广州达安基因股份有限公司舆情管理制度（2025年3月）
Governance Information Classification · 95% confidence The document is titled '舆情管理制度' which translates to 'Public Opinion Management System' and outlines the company's internal policies and procedures for managing public opinion and media information. It includes organizational structure, responsibilities, principles for handling information, reporting processes, and confidentiality obligations. There is no financial data, no mention of financial results, no regulatory filings or announcements about voting, dividends, or capital changes. It is a governance-related internal policy document approved by the board. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-03-28 Chinese
董事会对独立董事独立性评估的专项意见
Governance Information Classification · 95% confidence The document is a special opinion from the board regarding the independence evaluation of independent directors, referencing regulatory rules about independent directors and corporate governance. It does not contain financial data, audit results, or detailed management reports. It is a governance-related announcement about board members' independence compliance. The document length is short (472 characters), and it is a formal board opinion on director independence, fitting best under Governance Information (CGR).
2025-03-28 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.